Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06133231 · ClinicalTrials.gov registry record · NA

Optimizing Research With Diverse Families - Feasibility and Acceptability Study (FAST)

A NA study of Attention Deficit Hyperactivity Disorder and Irritable Mood, sponsored by Oregon Health and Science University.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06133231: Recruiting NA study of Attention Deficit Hyperactivity Disorder and Irritable Mood, sponsored by Oregon Health and Science University.

NCT06133231 is a NA study of Attention Deficit Hyperactivity Disorder and Irritable Mood that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 30 participants, below the 216-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06133231, a NA study of Attention Deficit Hyperactivity Disorder and Irritable Mood, is actively recruiting participants, sponsored by Oregon Health and Science University.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Evaluate feasibility and acceptability of recruiting Black and Hispanic families for an open label clinical trial of multinutrients while collecting real-time parent-reported child behavior data and collecting at-home biospecimens to explore their potential as biomarkers, in a study of pediatric ADHD.

Primary Outcome

Feasibility will be determined based on consumption of the number of capsules determined to be beneficial based on parent and child report of symptom improvement or side effects, typically 2-4 capsules per day (up to max of 8) and achieved when greater than or equal to 75% of recommended doses have been consumed as measured at week 4 and at week 8 by pill count.

Conditions Studied

Attention Deficit Hyperactivity Disorder Irritable Mood Emotional Dysfunction

Interventions

  • DIETARY_SUPPLEMENT Multinutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants

Study Locations (1)

Oregon

  • Oregon Health & Science University - Portland

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-01-06
Est. Completion 2026-01
Phase NA
Oregon Health and Science University

546 total trials

What NCT06133231 shows while recruiting

NCT06133231 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 216-participant average among 102 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (86% lower).

The record links to 3 conditions, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 1 intervention - of which Multinutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants is the first listed.

NCT06133231 reports a single indexed study location in Oregon.

Frequently Asked Questions

What is clinical trial NCT06133231 about?

NCT06133231 is a clinical study titled "Optimizing Research With Diverse Families - Feasibility and Acceptability Study (FAST)". Evaluate feasibility and acceptability of recruiting Black and Hispanic families for an open label clinical trial of multinutrients while collecting real-time parent-reported child behavior data and collecting at-home biospecimens to explore their potential as biomarkers, in a study of pediatric ADH...

What is the current status of trial NCT06133231?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-01-06. Estimated completion is 2026-01.

What conditions does trial NCT06133231 study?

This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder, Irritable Mood, Emotional Dysfunction.

What interventions are being tested in trial NCT06133231?

The interventions under investigation include: Multinutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06133231?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06133231 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Attention Deficit Hyperactivity Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06133231's enrollment target sits among peer trials

30 81st of 102 higher than 14 of 102 other Attention Deficit Hyperactivity Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Attention Deficit Hyperactivity Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06133231

Source: ClinicalTrials.gov NCT06133231, the US trial registry maintained by the National Library of Medicine. NCT06133231 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.